IMDX
Insight Molecular Diagnostics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.13
+0.24%Year over year
Reported trailing growth
- Revenue
- -60.8%
- EBITDA
- +23.7%
- EBIT
- +33.0%
- EPS
- +56.3%
- Free cash flow
- -30.3%
- Operating cash flow
- -17.0%
Forward estimates
Based on analyst estimates
- Revenue
- +4.9%
- EBITDA
- +33.3%
- EPS
- +39.5%
Three-year CAGR
- Revenue
- +61.8%
- EBITDA
- +18.8%
- EBIT
- +49.9%
- Net income
- +17.2%
- EPS
- +64.6%
- Free cash flow
- -19.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026